https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Immunic%2C_Inc.Immunic, Inc. - Revizia istoricului2026-05-17T19:31:01ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Immunic,_Inc.&diff=425253&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Immunic, Inc. listata cu simbolul US.IMUX ==Descriere companie== Immunic, Inc.(https://imux.com/), formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated imm...2024-09-18T18:04:38Z<p>Pagină nouă: Pagina dedicata companiei Immunic, Inc. listata cu simbolul US.IMUX ==Descriere companie== Immunic, Inc.(https://imux.com/), formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated imm...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Immunic, Inc. listata cu simbolul US.IMUX<br />
<br />
==Descriere companie==<br />
Immunic, Inc.(https://imux.com/), formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.IMUX" /><br />
<br />
==Ultimele stiri despre Immunic, Inc. (US.IMUX)==<br />
<dynamicpagelist><br />
category=US.IMUX<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.IMUX]][[Categorie:Stiri despre companii]]</div>Admin